Bio Pharma Dive
NOVEMBER 27, 2023
One year after the U.K. drugmaker withdrew the multiple myeloma drug from the U.S. market because of negative data, new study results might crack open the door to a relaunch.
Pharmaceutical Technology
NOVEMBER 27, 2023
Olvi-Vec is currently being evaluated in a Phase III trial as a treatment for platinum- resistant/refractory ovarian cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Worldwide Clinical Trials
NOVEMBER 27, 2023
By: Amy Raymond, PMP, PhD, Senior Director, Therapeutic Strategy Lead, Cellular & Genetic Medicines On November 16, the British regulatory body, Medicines and Healthcare products Regulatory Agency (MHRA) approved exagamglogene autotemcel (exa-cel) to treat severe sickle cell disease for patients ages 12 and up, becoming the first gene editing treatment to receive regulatory approval.
Rethinking Clinical Trials
NOVEMBER 27, 2023
The National Institutes of Health’s Office of Disease Prevention (ODP) issued a new funding opportunity to support implementation studies in treatment and prevention for alcohol, tobacco, and other drugs use and misuse in adult populations that experience health disparities. ODP and participating NIH Institutes and Centers are inviting applications for research projects that test innovative approaches to implementing screening, brief intervention, and referral to treatment or prevention fo
Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group
Let’s face it—most ethics and compliance training programs aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, captivating, and maybe even enjoyable! Join learning design expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training. We'll explore innovative strategies to bring traditionally dry topics to life, making them resonate with learners and drive tangible change.
Bio Pharma Dive
NOVEMBER 27, 2023
Yet, the company believes there were enough positive findings in the mid-stage trial to warrant further study of its drug, called XEN1101, in depression.
Pharma Times
NOVEMBER 27, 2023
The IRP will bring life-saving medicines to UK patients from 1 January 2024 - News - PharmaTimes
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
NOVEMBER 27, 2023
Around £330m will be invested in the software over the next seven years - News - PharmaTimes
Bio Pharma Dive
NOVEMBER 27, 2023
The planned $2.3 billion investment follows an earlier $6 billion commitment to expand manufacturing for drugs like its in-demand medicine Wegovy.
Pharmaceutical Technology
NOVEMBER 27, 2023
Autolus Theraputics is forging ahead with its T-cell cancer therapy, obe-cel, aimed at treating persistant adult ALL.
Fierce Pharma
NOVEMBER 27, 2023
Following the historic approval of the world’s first CRISPR-based gene-editing therapy in the United Kingdom this month, Vertex Pharmaceuticals has tapped its long-time manufacturing partner Roslin | RoslinCT, the CDMO arm of the Roslin Institute, is set to manufacture Vertex and CRISPR Therapeutics’ exa-cel “across the world” as part of Vertex’s global production network.
Advertisement
Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness
Pharmaceutical Technology
NOVEMBER 27, 2023
AbbVie epcoritamab: The monoclonal antibody, approved to treat certain B-cell lymphomas, received an FDA breakthrough therapy designation.
BioPharma Reporter
NOVEMBER 27, 2023
It is five years this month since a ground-breaking change in UK healthcare history happened â with doctors being able to prescribe cannabis-based medicines for the first time.
Pharmaceutical Technology
NOVEMBER 27, 2023
Sanofi and Regeneron plan to submit the supplemental data from the two Phase III trials of Dupixent to the US FDA by the end of 2023.
Fierce Pharma
NOVEMBER 27, 2023
After plotting $6 billion in production upgrades earlier this month, Novo Nordisk’s CEO Lars Fruergaard Jørgensen suggested the expansion outlay was just the start. | After plotting $6 billion in production upgrades earlier this month, Novo Nordisk’s CEO Lars Fruergaard Jørgensen suggested the expansion outlay was just the start. Now, some three weeks later, he’s putting his company’s money where his mouth is.
Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk
In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?
Pharmaceutical Technology
NOVEMBER 27, 2023
Mocravimod is currently being investigated in a global Phase III study in AML patients undergoing haematopoietic stem cell transplantation.
Fierce Pharma
NOVEMBER 27, 2023
Eli Lilly’s fortunes have turned quickly. | It was the second straight quarter where the overwhelming success of blood sugar regulating treatments were the dominant story in the biopharma industry. Eli Lilly and Novo Nordisk delivered the highest revenue gains, at 38% and 29%, respectively.
Pharmaceutical Technology
NOVEMBER 27, 2023
High-quality monitoring and trial oversight procedures are essential for avoiding the serious consequences that come protocol deviations, poor data quality, and regulatory issues.
BioSpace
NOVEMBER 27, 2023
Building on a previous 2021 collaboration, Bristol Myers Squibb is paying $100 million upfront for the development of five cardiovascular targets utilizing Avidity Biosciences’ antibody oligonucleotide conjugates.
Advertisement
Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.
Pharmaceutical Technology
NOVEMBER 27, 2023
Novartis has announced a voluntary recall of two lots of its 100mg/mL Sandimmune Oral Solution over crystallisation issues.
Antidote
NOVEMBER 27, 2023
The cornea is the outermost layer of the human eye, serving both as a protective covering and allowing light into the retina. To perform this function, the cornea is made up of several layers, the outermost of which is known as the epithelium.
Pharmaceutical Technology
NOVEMBER 27, 2023
The UK MHRA has issued a recall of batches of carbomer-containing lubricating eye gels due to potential microbial contamination.
pharmaphorum
NOVEMBER 27, 2023
Cultivating quality excellence in the clinical trials landscape Mike.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Pharmaceutical Technology
NOVEMBER 27, 2023
Everest Medicines has received approval from China's NMPA for its Nefecon to treat primary IgAN in adult patients.
pharmaphorum
NOVEMBER 27, 2023
EVERSANA’s alliance with Amazon Web Services (AWS) on the application of generative artificial intelligence (genAI) to the pharma sector has borne its first fruit – a new tool to tackle the time-consuming and error-prone task of getting medical and regulatory content approvals.
Pharmaceutical Technology
NOVEMBER 27, 2023
The UK NICE has recommended the usage of Alexion sebelipase alfa for the treatment of Wolman disease in infants and toddlers on the NHS.
pharmaphorum
NOVEMBER 27, 2023
Dupixent aces second COPD study, setting up FDA filing Phil.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Intouch Solutions
NOVEMBER 27, 2023
Attending college, choosing a major, and then finding a career that aligns with your education and evokes passion can be much more difficult than it seems. Many students may find their passion while in college but are unsure how that degree translates in the real world post-graduation. Simi Krishnan, Senior Vice President, Analytics, has worked in analytics for nearly 20 years and has grown her career in the field, starting as an analyst through data science and now in a leadership role.
pharmaphorum
NOVEMBER 27, 2023
Experts allay fears over pneumonia outbreak in China Phil.
XTalks
NOVEMBER 27, 2023
Amicus Therapeutics has recently received approval from the US Food and Drug Administration (FDA) for its drugs Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) for adults living with late-onset Pompe disease (LOPD) who are not improving on their current enzyme replacement therapy (ERT). “FDA approval of Pombiliti and Opfolda is a testament to the power of science, medicine and our passionate determination to improve the lives of people living with Pompe disease.
pharmaphorum
NOVEMBER 27, 2023
Lifeline for Wolman disease kids as NICE backs Alexion drug Phil.
Expert insights. Personalized for you.
277 
Let's personalize your content